Pharma Mar, S.A. (BME:PHM)

Market Cap	1.46B
Revenue (ttm)	174.86M
Net Income (ttm)	26.13M
Shares Out	17.57M
EPS (ttm)	1.49
PE Ratio	55.86
Forward PE	35.75
Dividend	0.65 (0.78%)
Ex-Dividend Date	Jun 12, 2024

Volume	24,535
Average Volume	62,534
Open	82.00
Previous Close	83.20
Day's Range	80.65 - 82.00
52-Week Range	26.16 - 105.80
Beta	-0.05
RSI	36.50
Earnings Date	Apr 25, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.